AMG 319

Drug Profile

AMG 319

Alternative Names: AMG319

Latest Information Update: 24 Feb 2017

Price : $50

At a glance

  • Originator Amgen
  • Developer Amgen; Cancer Research UK
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Head and neck cancer
  • Phase I Haematological malignancies

Most Recent Events

  • 01 Dec 2016 Amgen completes a phase-I trial for Haematological malignancies (Second-line therapy or greater) in USA (NCT01300026)
  • 16 Oct 2015 Phase-I development for Haematological malignancies (Second-line therapy or greater) is ongoing in USA (NCT01300026)
  • 19 Nov 2013 Amgen completes enrolment in its phase I trial for Haematological malignancies in USA (NCT01300026)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top